-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Lai Kai Pharmaceutical-B (02105.HK) announced that the new drug marketing application (NDA) for LAE002 (afuresertib) has been accepted by the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) to treat patients with recurrent or progressive disease (LA/c) with previous endocrine (with or without CDK4/6 inhibitors) treatment, accompanied by any PIK3CA/AKT1/PTEN changes.

Zhitongcaijing·08/12/2026 00:25:05
Listen to the news
Zhitong Financial App News, Lai Kai Pharmaceutical-B (02105.HK) announced that the new drug marketing application (NDA) for LAE002 (afuresertib) has been accepted by the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) to treat patients with recurrent or progressive disease (LA/c) with previous endocrine (with or without CDK4/6 inhibitors) treatment, accompanied by any PIK3CA/AKT1/PTEN changes.